This study demonstrates that carvacrol exerts multi-targeted anticancer effects in both HR+ (MCF-7) and TNBC (MDA-MB-231) BC cells by enhancing the BAX/BCL2 ratio, inducing apoptosis, reducing oxidative stress, and downregulating CD44+ cancer stem cell marker levels. This evidence concerns the gene BAX and breast cancer.